Search - tctmd.com

Presenter: Juan Luis Guti?rrez-Chico, Lorenz R?ber, Evelyn Regar, Takayuki Okamura, Carlo di Mario, Stephan Windecker, Gerrit-Anne van Es, Patrick W. Serruys

January 03, 2012

Presentation TCT 2012

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

Presenter: Ted S. Trajceski, Lulzim Brovina, Zivko Petrovski, Blerim Zuna, Borce Petrovski

January 03, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Presentation TCT 2012

Response of Endothelial Progenitor Cells To Antiproliferative Drugs Currently Used in Drug Eluting Stents

Presenter: Hao Xu, Kytai T. Nguyen, Lance S. Terada, Eric Fuh, Joseph A. Garcia, Emmanouil S. Brilakis, Deepak L. Bhatt, Subhash Banerjee

January 03, 2012

Presentation TCT 2012

Predictors Of Adverse Cardiac Events after PCI With GENOUS EPC-Coated Stents Compared To Drug Eluting Stents

Presenter: Boris Rudenko, Anatoly Savchenko, Serdgey Tereshchenko, Olga Cherkavskaya

January 03, 2012

Advertisement

Restenotic Pattern After Femoropopliteal Stenting Predicts Recurrence

OrbusNeich’s Genous™ Stent Is a Safe and Effective Option in Patients with ST-Segment Elevation Myocardial Infarction (STEMI)

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Study Urges Higher Cutoff for Troponin Elevation in Diagnosing MI

PEPCAD-DES: Paclitaxel-Coated Balloon Bests Plain Balloon for DES Restenosis

Meta-Analysis: Mixed Results Seen with First-Gen DES in STEMI Patients

Angiotensin Blocker Preserves Endothelial Function Better Than Calcium Antagonist

Boston Scientific Receives Industry's First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

SCAAR: Second-Generation DES Improve Hard Outcomes

DES Show Better Outcomes vs. BMS in Elderly, Though Use Declining

Tissue coverage and neointimal hyperplasia of overlap vs. non-overlap segments in drug-eluting stents 9-13 months after implantation: in vivo-assessment with optical coherence...

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Response of Endothelial Progenitor Cells To Antiproliferative Drugs Currently Used in Drug Eluting Stents

Predictors Of Adverse Cardiac Events after PCI With GENOUS EPC-Coated Stents Compared To Drug Eluting Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content